Erlotinib News and Research

RSS
Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.
High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Lung Cancer Alliance praises NCI's new ALCHEMIST trial

Lung Cancer Alliance praises NCI's new ALCHEMIST trial

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

CRIPTO1 role in TKI resistance elucidated

CRIPTO1 role in TKI resistance elucidated

CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Six-gene signature predicts survival after targeted therapy for NSCLC

Six-gene signature predicts survival after targeted therapy for NSCLC

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Survival differences after docetaxel, erlotinib are EGFR dependent

Survival differences after docetaxel, erlotinib are EGFR dependent

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

New database allows researchers to match old drugs for new diseases

New database allows researchers to match old drugs for new diseases

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed plus erlotinib shows benefits in NSCLC

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014